What is CUSIP 04962H506?

CUSIP 04962H506 is the security identifier used in SEC filing datasets for ATOS - ATOSSA THERAPEUTICS, INC. - Common Stock.

Who owns ATOS - ATOSSA THERAPEUTICS, INC. - Common Stock based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

Security Snapshot

ATOSSA THERAPEUTICS, INC. - Common Stock (ATOS) Institutional Ownership

CUSIP: 04962H506

13F Institutional Holders and Ownership History from Q2 2018 to Q1 2026

13F reference period

n/a

Institutions Reporting

Shares (Excl. Options)

n/a

Price

$0.57

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period

Security type / class: Equity / Common Stock
Symbol: ATOS on Nasdaq
Shares outstanding: 129,337,627
SEC-reported price per share: $0.57
Insider filing price: $0.57

13F Shares, Excluding Options vs Price

13F Value, Excluding Options

Total Investors

Filing notes and source

Key facts

ATOS - ATOSSA THERAPEUTICS, INC. - Common Stock is tracked under CUSIP 04962H506.
13F reference-period holder data is not available.
3 significant owners is listed from Schedule 13D/13G reporting.

Change

Holder data for the Q2 2026 reference period is not available.
Available periods remain in the history table; they do not substitute for the headline period.

Research use

You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

04962H506

13F reference period

n/a

13F holders

13D/G owners

CIK / CUSIP context first

ATOS full holder history ATOSSA THERAPEUTICS, INC. SEC filings ATOSSA THERAPEUTICS, INC. company facts ATOSSA THERAPEUTICS, INC. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 04962H506:

Q1 2026 (0 holders) Q4 2025 (62 holders) Q3 2025 (63 holders) Q2 2025 (82 holders) Q1 2025 (82 holders) Q4 2024 (83 holders) Q3 2024 (85 holders) Q2 2024 (74 holders) Q1 2024 (64 holders) Q4 2023 (47 holders)

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows

Security

ATOS

Filer	Ownership	Holdings Value	Nb Shares	Reporting Name	Report Period
VANGUARD GROUP INC	4.5%	$4,841,495	5,833,127	The Vanguard Group	30 Jun 2025
CVI Investments, Inc.	4.3%	$4,530,000	5,662,500	CVI Investments, Inc.	31 Dec 2024
BlackRock, Inc.	1.6%	$1,717,392	2,094,891	BlackRock, Inc.	30 Jun 2025

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods

Headline period

n/a

Rows shown

1-25 of 32

Period	13F Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2026 Q1	0	$0	-$9,307,564	$0	$0	$0.57	0
2025 Q4	21,950,342	$12,944,911	+$1,318,964	$41,477	$74,517	$0.59	62
2025 Q3	19,380,482	$16,800,163	-$1,648,909	$85,931	$69,163	$0.87	63
2025 Q2	21,349,209	$17,720,003	-$5,653,305	$78,562	$10,541	$0.83	82
2025 Q1	28,359,111	$19,084,789	-$1,341,003	$35,685	$43,491	$0.67	82
2024 Q4	29,931,066	$28,256,526	+$2,338,368	$85,521	$38,142	$0.94	83
2024 Q3	27,342,806	$41,556,220	+$1,106,466	$139,415	$707,641	$1.52	85
2024 Q2	26,185,969	$31,162,750	+$6,136,738	$99,484	$480,403	$1.19	74
2024 Q1	19,247,212	$34,645,211	+$6,651,468	$148,320	$171,000	$1.80	64
2023 Q4	15,977,339	$14,108,531	-$98,734	$36,080	$143,616	$0.88	47
2023 Q3	16,179,139	$11,915,565	-$5,714	$47,100	$129,174	$0.74	50
2023 Q2	16,001,766	$20,161,211	-$384,693	$35,154	$326,434	$1.26	48
2023 Q1	16,381,798	$11,876,091	-$1,061,782	$32,236	$143,214	$0.72	41
2022 Q4	17,942,376	$9,491,902	-$744,052	$62,086	$217,254	$0.53	48
2022 Q3	19,012,323	$15,840,090	-$3,865,790	$242,000	$348,000	$0.83	44
2022 Q2	23,270,576	$25,392,308	-$11,443,285	$325,000	$463,000	$1.09	61
2022 Q1	33,773,484	$42,226,500	-$5,308,588	$610,000	$638,000	$1.25	71
2021 Q4	39,320,369	$63,309,166	+$10,803,111	$1,577,000	$3,563,000	$1.60	82
2021 Q3	30,993,684	$101,545,957	-$24,704,471	$5,654,000	$12,721,000	$3.26	86
2021 Q2	35,452,360	$224,051,807	+$172,782,844	$35,794,000	$42,675,000	$6.32	80
2021 Q1	10,827,609	$22,844,136	+$19,269,267	$1,477,000	$4,432,000	$2.11	50
2020 Q4	1,579,871	$1,500,720	+$453,590	$41,000	$91,000	$0.95	12
2020 Q3	738,286	$1,785,592	+$1,033,409	$33,000	$61,000	$2.42	21
2020 Q2	311,346	$1,182,680	+$252,483	$40,000	$74,000	$3.79	9
2020 Q1	239,786	$319,620	-$72,670		$0	$1.33	7